Effective treatment of premenstrual violence in major depression: Augmentation with aripiprazole

Chang Gung Medical Journal

Volumn 31, Issue 4, 2008, Pages 402-406

  Yao, Yi Chun ^a   Chiang, Pi Hui ^c   Hsiao, Mei Chun ^a,b   Liu, Chia Yih ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c Chiayi University   (Taiwan)

Author keywords

Aripiprazole; Premenstrual syndrome; Violence

Indexed keywords

ARIPIPRAZOLE; PAROXETINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC TEST; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; IRRITABILITY; LUTEAL PHASE; MAJOR DEPRESSION; MENSTRUAL CYCLE; RATING SCALE; REMISSION; TREATMENT FAILURE; TREATMENT RESPONSE; VIOLENCE; VISUAL ANALOG SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; PIPERAZINES; PREMENSTRUAL SYNDROME; PSYCHOMOTOR AGITATION; QUINOLONES; VIOLENCE;

EID: 48749104804     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hsiao MC, Liu CY, Chen KC, Hsieh TT. Characteristics of women seeking treatment for premenstrual syndrome in Taiwan. Acta Psychiatr Scand 2002;106:150-5.
2. Hsiao MC, Hsiao CC, Liu CY. Premenstrual symptoms and premenstrual exacerbation in patients with psychiatric disorders. Psychiatry Clin Neurosci 2004;58:186-90.
3. Dalton K. Cyclical criminal acts in premenstrual syndrome. Lancet 1980;2:1070-1.
4. Halbreich U, Monacelli E. Some clues to the etiology of premenstrual syndrome/premenstrual dysphoric disorder. Prim Psychiatry 2004;11:33-40.
5. Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 2006;15:57-69.
6. Miller MN, Miller BE. Premenstrual exacerbations of mood disorders. Psychopharmacol Bull 2001;35:135-49.
7. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990;13:227-36.
8. Robinson GE. Premenstrual syndrome: current knowledge and management. CMAJ 1989;140:605-11.
9. Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990;20:129-34.
10. Yonkers KA, White K. Premenstrual exacerbation of depression: one process or two? J Clin Psychiatry 1992;53:289-92.
11. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998;44:839-50.
12. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11.
13. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry 2006;67:13-21.
14. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005;66:1326-30.
15. Patkar AA, Peindl K, Mago R, Mannelli P, Masand PS. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006;8:82-7.
16. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66:1216-20.
17. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005;86:99-104.
18. Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of: 9-11er patients. Int Clin Psychopharmacol 2005 augmentor of selective serotonin reuptake inhibitors in depression and anxiety dselective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11.
19. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-40.